At siRNAgen Therapeutics, we are committed to addressing the unmet needs of patients with osteoarthritis (OA), a degenerative joint disease affecting over 500 million people worldwide. Characterized by cartilage breakdown, chronic pain, and reduced mobility, OA represents a significant global health challenge. Our proprietary SAMiRNA™ platform leverages RNA interference (RNAi) to develop innovative therapies aimed at modifying disease progression and improving quality of life for OA patients.
We are pioneering RNAi-based therapies to target the molecular drivers of OA, such as inflammation and cartilage degradation, offering potential disease-modifying osteoarthritis drugs (DMOADs). Key aspects of our OA program include:
Our platform enables precise delivery of siRNA to joint tissues, targeting key pathways like IL-1, TNF, or ADAMTS-5 to halt cartilage loss and reduce inflammation.
Designed for sustained drug retention in the joint, our therapies aim to overcome the limitations of traditional treatments by providing long-acting, localized effects.
Our OA pipeline is in preclinical development, with plans to advance candidates into clinical trials, building on the success of our lead program, SRN-001 for IPF.
We partner with leading academic and industry experts to accelerate the development of transformative OA therapies.